Meditation and Stretching for Post Treatment Lyme Disease Syndrome

Not Applicable

Terminated

Conditions: Post Treatment Lyme Disease Syndrome

Interventions: Behavioral: Kundalini Yoga

Registration Number: NCT02344537

Lead Sponsor: Research Foundation for Mental Hygiene, Inc.

Brief Summary: The investigators wish to conduct a preliminary study to examine the efficacy of meditation among patients with Post Treatment Lyme Syndrome (PTLDS). Specifically, the investigators will use the breathing, meditation, and stretching techniques common to Kundalini Yoga practice. The investigators plan to assess the degree in which this practice can reduce Post-Treatment Lyme Disease symptoms. Because fatigue and pain are so common among patients with PTLDS, the primary focus of this study will be fatigue and pain. Secondary outcomes will include cognitive complaints, physical and mental functioning, medical utilization, somatic symptoms, and psychopathology.

Detailed Description: The CDC reports that approximately 10-20% of patients treated for Lyme disease with the IDSA-recommended 2-4 week course of antibiotics will continue to have symptoms of fatigue, pain, or joint and muscle aches despite prior antibiotic treatment. The symptoms can last months or even years after treatment. The medical community officially calls this condition "Post-treatment Lyme disease Syndrome" (PTLDS) but some have called it "chronic Lyme disease." Because some patients with PTLDS continue to have ongoing symptoms despite many additional courses of antibiotics beyond the standard course, alternative non-antibiotic treatment programs need to be explored. The proposed study seeks to evaluate the efficacy of meditation among those patients that have been previously treated for Lyme disease but are still continuing to experience prominent symptoms of fatigue and/or pain.

During this study, patients will be screened initially over the telephone to assess eligibility, sign consent with the study treating psychiatrist, and complete self-report questionnaires. Forty patients will be enrolled. Of these, 20 will be randomly assigned to meditation group therapy and 20 will be assigned to a wait-list. Assessments will be conducted prior to treatment, at 4 weeks and at 8 weeks. There will also be a 6 month follow-up by questionnaire and telephone interview. Study participants randomized to the wait-list control group will then be offered, after 8 weeks, the option of joining a meditation group for 8 weeks. Each meditation group will be composed of 6-8 subjects.

Should this study find evidence suggesting that meditation therapy is helpful in reducing the symptoms of PTLDS, this would be a valuable finding that would lead to a larger study as it has important public health implications for many individuals now quite disabled with these chronic symptoms.

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 26

Inclusion Criteria

History of prior diagnosis of Lyme Disease at least 6 months prior to assessment
1. EM Rash seen by health professional
  
  -OR-
2. History of physician diagnosed disseminated Lyme disease
Previously treated for Lyme Disease with antibiotics appropriate for stage of disease
Current symptoms of PTLDS started within 6 months after getting Lyme disease
Current symptoms have been present for at least the last 6 months.
Between the ages of 18 and 65, English speaking, male or female
Primary complaint of fatigue or pain meeting predetermined severity criteria
Individuals whose medical and/or psychiatric treatment has been stable for the prior 8 weeks
Individuals who agree to not start a new treatment for PTLS during the course of the study; this applies to both those assigned to the control wait list group and those assigned to the experimental group.

Exclusion Criteria

Individual with another reasonable medical explanation (other than Lyme) that might better account for current fatigue or pain (e.g., Thyroid Disease, Anemia, Rheumatoid Arthritis)
Individual with a major psychiatric diagnosis that might make study participation difficult (e.g, Dissociative Identity Disorder, Psychosis, Post Traumatic Stress Disorder, Substance abuse with the prior 6 months, Pain Disorder treated with opiate-based medication)
Individuals with severe depression
Individuals with Physical disability that might make study participation difficult
Individuals whose current medical status is so severe or unstable that participation in the study (and not receiving new treatments from other providers) would be difficult.
Unwillingness to complete questionnaires, speak with study research assistant, or dedicate twenty minutes daily to meditation and stretching
Suicide attempts within the last 6 months or current suicidal thoughts
Individuals unwilling to delay starting optional treatment for Lyme disease for the duration of the study
Individuals with a prior lifetime practice of at least one month of daily practice of MBSR or mindfulness or those who currently practice daily meditation or yoga

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Meditation Group Therapy	Kundalini Yoga	Kundalini Yoga incorporates mindfulness practice with a triad of stretching, breathing, and meditation. The three components of treatment consist of muscular relaxation/stretching exercises, a meditation period characterized by a directed breathing exercise, and then a guided meditation.

Primary Outcome Measures

Name	Time	Method
Fatigue (Self-reported Level of Fatigue as Measured by the PROMIS Fatigue Scale)	Assessed at week 4 and 8; week 8 value is reported (primary endpoint). 6 month assessment not conducted.	Self-reported assessment of fatigue as measured by the 7 item PROMIS Fatigue Scale. The raw score range is 7-35. The raw score is converted to a T-score with a mean of 50 and a standard deviation of 10; the results reported here are the T-scores. HIgher scores indicate greater fatigue
Pain Interference (PROMIS Pain Interference Scale)	Assessed at weeks 4 and 8; week 8 data reported (primary endpoint). 6 month assessment not conducted.	Self-reported assessment of pain interference as measured by the 6-item PROMIS Pain Interference Scale. The raw score range is 6-30. The raw score is converted to a T-score with a mean of 50 and a standard deviation of 10; the results reported here are the T-scores. HIgher scores indicate greater pain interference.
Global Health (Self-reported Levels of Satisfaction With Global Health)	Assessed at week 4 and 8; week 8 is reported (primary endpoint). 6 month assessment not conducted.	Self-reported assessment of satisfaction with global health as measured by the 1st item ( a 5 point scale, range 1-5) on the PROMIS Global Heath Scale where higher scores indicate greater satisfaction with health.

Secondary Outcome Measures

Name	Time	Method
PROMIS Social Satisfaction	Assessed at 4 and 8 weeks; 8 week values are reported (primary endpoint). 6 month assessment was not conducted. .	Assesses satisfaction with social functioning. 8 item scale. Raw score range i 8-40). The raw score is converted to a T-score with a mean of 50 and a standard deviation of 10; the results reported here are the T-scores. HIgher scores indicate greater satisfaction with social functioning.
Applied Cognition General Concerns Short-form	Assessed and 4 and 8 weeks; the 8 week results are reported (primary outcome timepoint). The 6 month assessment was not conducted.	This self-report NeuroQoL measure assesses general concerns about cognition. This is an 8 item scale, with raw scores ranging from 8 to 40. The raw score is converted to a T-score with a mean of 50 and a standard deviation of 10; the results reported here are the T-scores. Higher scores mean fewer cognitive concerns.
Physical Functioning (as Measured by the PROMIS Physical Functioning Scale)	Assessed at weeks 4 and 8; week 8 data reported (primary endpoint). Month 6 assessment not conducted.	Self-reported assessment of physical functioning as measured by the PROMIS Physical Functioning 8 item Scale. Raw score range 8-40. The raw score is converted to a T-score with a mean of 50 and a standard deviation of 10; the results reported here are the T-scores. HIgher scores indicate better physical functioning.
General Symptom Questionnaire-30 (Self-reported Symptom Burden)	Assessed at 4 and 8 weeks; 8 week values are reported (primary endpoint). Month 6 assessment not conducted.	Self-reported assessment of symptom burden as measured by the 30 item multisystem Global Symptom Questionnaire. Range is 0-120 where higher scores indicate greater symptom burden
Beck Depression Inventory	Assessed at weeks 4 and 8; 8 week data is reported (primary endpoint). Month 6 assessment not conducted.	Self reported mood as measured by the 21 item Beck Depression Inventory. Range is 0-63 where higher scores indicate greater depression.

Trial Locations

Locations (2): New York State Psychiatric Institute
🇺🇸
New York, New York, United States
Private Practice Office of Dr. Alexander
🇺🇸
Southport, Connecticut, United States